)
Edge23 Jan 2026
Death, Taxes, and Garbage: The Story of WM
How Waste Management turned garbage into one of America's most stable business models through landfills, regulation, and nationwide scale.
Neurocrine Biosciences
Neurocrine Biosciences (NBIX) investor relations material
Neurocrine Biosciences 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.44th Annual J.P. Morgan Healthcare Conference summary12 Jan, 2026
Strategic themes and business momentum
Emphasized strong momentum and strategic, balanced diversification as key themes for 2026, with a focus on expanding both commercial and R&D operations.
Workforce has grown to 2,000, supporting a proven track record in discovering, developing, and commercializing first-in-class medicines.
INGREZZA and CRENESSITY are both commercialized in the U.S., with CRENESSITY positioned as the next blockbuster in rare endocrine disease.
Sales force expansion underway to support both brands and drive further growth.
Revenue diversification is now achieved, with CRENESSITY contributing alongside INGREZZA for the first time since 2017.
R&D engine and pipeline strategy
R&D engine is fully operational, targeting four new phase I, two new phase II, and at least three phase III programs annually, aiming for one new medicine every two years by decade's end.
Pipeline diversification includes small molecules, peptides, antibodies, and gene therapies, with a philosophy of matching modality to disease target.
Internal innovation is prioritized, complemented by strategic business development.
12 programs are in clinical development: 8 in phase I, 2 in phase II, and 2 in phase III, with six new phase I studies planned for the year.
New study initiations include gene therapy for Friedreich's ataxia, two obesity programs, HPA axis dysregulation, CRF antagonists, and immunology programs.
Neuropsychiatry and endocrinology portfolio highlights
Neuropsychiatry pipeline includes first-in-class AMPA-PAM for major depressive disorder and Derecladine for schizophrenia and bipolar mania, both in phase III.
Muscarinic portfolio spans agonists and antagonists across multiple disease states and stages, increasing probability of success.
Next-generation VMAT2 inhibitors (NBI-890, NBI-675) aim to extend leadership in VMAT2 biology.
Endocrinology pipeline leverages 30 years of CRF biology, with a two-pronged strategy: CRF1 for HPA axis diseases and CRF2 for metabolic disorders, including obesity.
Proprietary incretin and combination approaches are being developed for differentiated obesity treatments.
CRF2 obesity program differentiation
Path to one new medicine every 2 years
Impact of 2-year CRENESITY data on adoption
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Neurocrine Biosciences earnings date
Q4 202511 Feb, 2026
Neurocrine Biosciences
Next Neurocrine Biosciences earnings date
Q4 202511 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Neurocrine Biosciences, Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of therapies for neurological, endocrine, and psychiatric disorders. The company focuses on treatments for conditions such as movement disorders, adrenal diseases, and mental health challenges. Neurocrine Biosciences, Inc. is headquartered in San Diego, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage